LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
Thomas Powles,V. Chistyakov,V. Beliakouski,Andrey Semenov,Els Everaert,Y. Baranau,Víctor Moreno,Begoña P. Valderrama,Yann Vano,G. Del Conte,Yohann Loriot,Taek Won Kang,Meggan Tammaro,Anne O’Hagan,Maryam Hosseini,Spyros Triantos,Harleen Chhabra,Ademi Santiago-Walker,Arlene O. Siefker‐Radtke
出处
期刊：Annals of Oncology [Elsevier BV] 日期：2021-09-01卷期号：32: S1303-S1303被引量：14
PDF的下载单位、IP信息已删除
(2025-6-4)
老的火龙果
Criminology34
xinbadake
GingerF
369ninja
the_coco
OK
DW
cdercder
悦耳的怀寒
MchemG
12Nightz
Kao
初景
Nole
YifanWang
罗Eason
无极微光
郢儿
牧青
皖公网安备34019202002308
